InVivo Therapeutics Holdings Corp (NVIVQ)

[gp22]

NVIV: Next stock offering has to be 40% below $1.80 to lure investors. They need cash right now. Major drop off cliff developing. Sad for sure.

[BesaoT35]

Thanks Frankestin. Very few people follow this company. With reverse splits and massive dilutions anyone who was long term faithful was wiped out completely.

[Frankestin]

https://investors.invivotherapeutics.com/presentations

[BesaoT35]

There is not a lot of chatter about INSPIRE 2.0 here. The phase 3 results get announced in the first quarter of 2023.

[Frankestin]

Do not sell if you have a loss, wait a little while, in a few months this takes off!
IMO is promising!

https://journals.lww.com/neurosurgery/Fulltext/2022/06000/Acute_Implantation_of_a_Bioresorbable_Polymer.3.aspx

[Frankestin]

Do not sell if you have a loss, wait a little while, in a few months this takes off!
IMO is promising!

https://journals.lww.com/neurosurgery/Fulltext/2022/06000/Acute_Implantation_of_a_Bioresorbable_Polymer.3.aspx

[Pt3]

Offering close Tuesday

[FooBarAndGrill]

Holey S##t what a pump-n-dump this morning. Stocktwits was on fire!

[crudeoil24]

Shelf placement: InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
8:00 am ET October 7, 2022 (BusinessWire) Print
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or pre-funded warrants in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 1,714,286 shares of the Company's common stock. The preferred investment options have an exercise price of $5.05 per share, will be immediately exercisable upon issuance, and will expire five and one-half (5.5) years from the date of issuance. The combined purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and the associated preferred investment option is $5.25.

[BoilerRoom]

$NVIV here we go

[BoilerRoom]

$NVIV $20.00 tomorrow imo

[BoilerRoom]

Possibly or sooner

[itrade60]

$100 in 2 weeks

[BoilerRoom]

$NVIV Weeeeeeeeeeeeeee

[BoilerRoom]

$NVIV $20.00 tomorrow

[BoilerRoom]

$NVIV folks your not late

[BoilerRoom]

$NVIV great day here and much more to come

[Frankestin]

[BesaoT35]

This was at a pps of above 13 for a brief time roughly a month ago. What was the ‘reason for that 200% run up that happened in one morning? Any possible causes that could be a plausible true reason even if not proven? Thanks

[BesaoT35]

Will NVIV do a dilutive offering before or after the INSPIRE 2 results get announced? If before then it might be better to wait and buy after dilution. If before then that would be better for current shareholders.

INSPIRE 1 was a success. That would mean that INSPIRE 2 is probably a success. I am concerned about having the IP rights expire in a short period of time.

[bandit007]

That was a quick $3:share profit!

[bandit007]

That was a quick $3:share profit!

[bandit007]

Liking the pump sofar. I’m already up over $1/share.

[NCMadman]

stock twits says pump and dump

[Frankestin]

1,5 milion shares already!
Why?

[BesaoT35]

Inspire 1 and Inspire 2 have taken a long time to complete. We are at 19 of 20 patients in Inspire 2. The patents to protect our intellectual property must now have a limited time left until expiration. Perhaps the new addition of stem cells and nerve growth factors in future trials would extend patent protection for a much longer time. Are we filling for new patents?

[BesaoT35]

Now the market cap is $4.9 million. If Inspire 2.0 is a success that would be worth how much. After this comes stem cells and nerve growth factors in addition to the Spinal scaffold implant.

I think we have enough cash to finish the Inspire 2.0.

We have more cash on hand than the market cap of the company. Does that mean that our intellectual property is worth nothing or less than nothing?

[BesaoT35]

The market cap is $7 million. If Inspire 2 gets fully enrolled and is successful what would be the market cap? The company has two or three times the market cap in cash. One year or so of cash burn runway.

Why are the CEO salaries so high?

[Frankestin]

The Company’s consolidated financial statements as of December 31, 2021 were prepared under the assumption that the Company will continue as a going concern. At December 31, 2021, the Company had cash and cash equivalents of $19.0 million. Given the Company’s current plans, the Company estimates cash resources will be sufficient to fund its operations through the second quarter of 2023.
MC 7,5
Mmmmm
I hold

[BesaoT35]

The 35 patients I think are a total of Inspire 1.0 and Inspire 2.0 patients. It was 15 patients in Inspire 1.0 when a patient died that was later determined not to be due to the NSS implantation. The FDA at the time also wanted a control arm that we did not have in Inspire 1.0.

Inspire 2.0 is 20 patients total of which 17 have enrolled to date that we know of. 15 + 20 = 35. This is how I see the meaning of the total number of patients having a total of 35.

[Frankestin]

I remember 20
Here it says 35!
https://clinicaltrials.gov/ct2/show/NCT03762655?cond=Neuro-Spinal+Scaffold&draw=1&rank=2
Could they have changed the number?

[Frankestin]

we grope in the dark

[BesaoT35]

I am in this still hoping that Inspire 2.0 is a success similar to Inspire 1.0. Then after approval by the FDA the addition of stem cells and/or nerve growth factors could help patients even better perhaps.

Growing neural connections could have applications beyond spinal cord injury.
Connecting computer interfaces to the brain may also use similar technology.

What surprises me is that there is so little interest in NVIV and so little hope for success. Early investors have been wiped out entirely. The latest investors are also bag holders. The CEO makes more than $1million per year.

Is the CEO that you met in 2012 now in prison?

[REAGAN]

Are you still in this? The O/S is small on this and 1/2 owned by insiders. This company been around for a long time. One of few to get to trials. I met the ceo at the time in 2012

[BesaoT35]

Would a reverse split and then a discounted stock offering be in the near future for NVIV. Would that harm the interests of our senior management officers? I think they must accept only cash compensation.

[BesaoT35]

There are since last reported 4 more patients until enrollment in Inspire 2 is complete. They will not report each individual new enrollment it seems. They will report when enrollment is complete however I think.

I remember a long time ago when Inspire 1 was going there was an excitement and a dramatic run up in price per share. We had a few deaths that were unrelated but the stock did tank. The FDA made the testing more arduous at that time also.

Now it seems that if results are good that we are farther down the road than we were then when investors were so optimistic.

[CyrusDaVirus]

Getting some hits hmm

[BesaoT35]

The presentation is compelling. Thanks to Frankenstein for posting it. There are roughly 1,000 suitable patients in one year. We need 4 more to complete the study. The success so far in conversions has been with no stem cells at all just the scaffold yet it is successful. I have an intuition that stem cells and nerve growth factors could add substantially to successful outcomes but that could be just hopeful thinking on my part.

I do not know whether opting to be in the study means that patients could have all their treatments covered which might be an additional incentive for a patient to opt in.

4 more patients out of 1000 potential candidates does not seem so far fetched. I believe that they will achieve full enrollment and given the success of Inspire 1.0 that Inspire 2.0 should be successful enough also to get approved.

There are very few believers in NVIV at this time given the previous stock performance and Frank Reynolds former CEO that went to jail for fraud.

There is one analyst with a $30 price target.

[Frankestin]

INSPIRE 2.0: Active Pivotal Study of the Neuro-Spinal ScaffoldTM
? Encouraging data from single-arm INSPIRE 1.0 study supports follow-on study
? 20-patient (two-arm, 10 subjects in each study arm) randomized, controlled trial designed to provide
clinical data that will supplement the existing INSPIRE 1.0 clinical results
? As of September 8, 2021, 15 patients have been enrolled and 18 sites are open for enrollment
? Due to recent variability in enrollment patterns, Company is not estimating at this time when enrollment may be complete
Desire to Expand Pipeline beyond the Neuro-Spinal Scaffold with
Technologies that align with InVivo’s Core Competencies
? Ongoing Joint Research Collaboration with Q Therapeutics, Inc.: Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal ScaffoldTM with stem cells

[Frankestin]

https://investors.invivotherapeutics.com/static-files/b31472d0-67d0-4eda-8359-04ba5f7bba2e

[Argus63]

Great entry point!

GLTA

[mining101]

Useless

[Byurwherevergirl]

Waiting

[BesaoT35]

Going back 6 years gets you $12,000 invested in NVIV then being worth $0.82 now.

[BesaoT35]

Taking a view back 5 years I see a drop from 5000 to 0.81 when reverse splits get accounted for.

[BesaoT35]

Once nerve growth factors and stem cells get used with the neuro-spinal scaffold NSS it could and hopefully will result in a dramatic improvement in nerve growth or axon growth outcomes.

Something like that could have broader uses in other neurodegenerative diseases, stroke or various psychiatric diseases perhaps.

The current Inspire 2.0 is only using the scaffold I think (correct me if I am wrong) that gets implanted into the spine. It alone shows improved spinal function scores and clinical outcomes.

I do not know of any direct competitors. Again please correct me if I am wrong about competition. I would expect a rising interest by investors and larger biotech companies in NVIV if clinical outcomes stay positive or become more positive.

Early investors have lost more than 99% of their early invested capital in NVIV so far, talking long term. It is the most negative performance , or one of the worst, that can be found for any stock long term that is not yet delisted.

Could this long decline reverse itself?

[Frankestin]

It is rewarding to see our continued progress in advancing the Neuro-Spinal Scaffold™ towards our complete HDE submission, and we value the FDA’s continued collaboration with us to help achieve this goal.

[BesaoT35]

How many patients are already enrolled in INSPIRE 2 and how many are required to complete the study? Thanks.

[AL BUNDY STOCKS]

Patience is paying off here...

[mining101]

What’s the point selling at these levels? Anybody has a few more insights on the company?